Ousama Al Haj, director for UAE, Bahrain, Oman & Qatar at AstraZeneca, highlights the company’s substantial growth and favourable position in the Gulf markets, explains how the company is overcoming the local healthcare dynamics by partnering with local authorities to offer patients’ platforms instead of products, and analyzes AstraZeneca’s future with the launch of its new oncology portfolio and expanded new indications of the current portfolio.
The UAE and the rest of the GCC countries are setting the standard of fast track registration for other international markets
